LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention

Oncogene

Volumn 34, Issue 1, 2015, Pages 39-52

  Stampolidis, P ^a   Ullrich, A ^a   Iacobelli, S ^b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b Mediapharma srl   (Italy)

Author keywords

Cancer biomarker; Extracellular matrix; Integrin signalling; LGALS3BP; Therapeutic target

Indexed keywords

ANTIBODY; CARRIER PROTEIN; GLYCOPROTEIN; INTEGRIN; LGALS3BP PROTEIN, HUMAN; LIGAND; PROTEIN BINDING; TUMOR ANTIGEN; TUMOR MARKER;

CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DISEASE COURSE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES; ANTIGENS, NEOPLASM; CARRIER PROTEINS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; INTEGRINS; LIGANDS; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84890520673     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.548     Document Type: Article

References (51)

1. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326: 1216-1219.
2. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012; 196: 395-406.
3. Mbeunkui F, Johann Jr. DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009; 63: 571-582.
4. Huxley-Jones J, Foord SM, Barnes MR. Drug discovery in the extracellular matrix. Drug Discov Today 2008; 13: 685-694.
5. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61: 198-223.
6. Martinez VG, Moestrup SK, Holmskov U, Mollenhauer J, Lozano F. The conserved scavenger receptor cysteine-rich superfamily in therapy and diagnosis. Pharmacol Rev 2011; 63: 967-1000.
7. Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994; 69: 172-176.
8. Ozaki Y, Kontani K, Hanaoka J, Chano T, Teramoto K, Tezuka N et al. Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Cancer 2002; 95: 1954-1962.
9. Sardana G, Marshall J, Diamandis EP. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin Chem 2007; 53: 429-437.
10. Xue H, Lu B, Lai M. The cancer secretome: a reservoir of biomarkers. J Transl Med 2008; 6: 52.
11. Ulmer TA, Keeler V, Loh L, Chibbar R, Torlakovic E, Andre S et al. Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer. J Cell Biochem 2006; 98: 1351-1366.
12. Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Anticancer Res 1988; 8: 761-764.
13. Cesinaro AM, Natoli C, Grassadonia A, Tinari N, Iacobelli S, Trentini GP. Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. J Invest Dermatol 2002; 119: 187-190.
14. Carlin CR, Knowles BB. Identification of a 90 000-Dalton cell surface glycoprotein with elevated expression in human hepatoma cells. Exp Cell Res 1983; 147: 359-367.
15. Iacovazzi PA, Trisolini A, Barletta D, Elba S, Manghisi OG, Correale M. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med 2001; 39: 961-965.
16. Kashyap MK, Harsha HC, Renuse S, Pawar H, Sahasrabuddhe NA, Kim MS et al. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther 2010; 10: 796-810.
17. Park YP, Choi SC, Kim JH, Song EY, Kim JW, Yoon DY et al. Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int J Cancer 2007; 120: 813-820.
18. Zhang DS, Jiang WQ, Li S, Zhang XS, Mao H, Chen XQ et al. [Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma]. Ai Zheng 2003; 22: 870-873.
19. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R et al. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004; 101: 1609-1615.
20. Srirajaskanthan R, Caplin ME, Waugh MG, Watkins J, Meyer T, Hsuan JJ et al. Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes. Mol Cell Proteomics 2010; 9: 656-666.
21. Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004; 19: 551-556.
22. Fornarini B, D'Ambrosio C, Natoli C, Tinari N, Silingardi V, Iacobelli S. Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood 2000; 96: 3282-3285.
23. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 1994; 269: 18401-18407.
24. Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J 1998; 17: 1606-1613.
25. Block AS, Saraswati S, Lichti CF, Mahadevan M, Diekman AB. Co-purification of Mac-2 binding protein with galectin-3 and association with prostasomes in human semen. Prostate 2011; 71: 711-721.
26. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010; 339: 269-280.
27. Geiger B, Yamada KM. Molecular architecture and function of matrix adhesions. Cold Spring Harb Perspect Biol 2011; 3: a005033.
28. Han S, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 2006; 66: 315-323.
29. Oktay M, Wary KK, Dans M, Birge RB, Giancotti FG. Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. J Cell Biol 1999; 145: 1461-1469.
30. Bode AM, Dong Z. The functional contrariety of JNK. Mol Carcinog 2007; 46: 591-598.
31. Dreskin SC, Thomas GW, Dale SN, Heasley LE. Isoforms of Jun kinase are differentially expressed and activated in human monocyte/macrophage (THP-1) cells. J Immunol 2001; 166: 5646-5653.
32. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12: 1-13.
33. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2: 91-100.
34. Van Slambrouck S, Jenkins AR, Romero AE, Steelant WF. Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer. Int J Oncol 2009; 34: 1717-1726.
35. Faccio R, Grano M, Colucci S, Villa A, Giannelli G, Quaranta V et al. Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. J Cell Sci 2002; 115: 2919-2929.
36. Snider JL, Allison C, Bellaire BH, Ferrero RL, Cardelli JA. The beta1 integrin activates JNK independent of CagA, and JNK activation is required for Helicobacter pylori CagA + -induced motility of gastric cancer cells. J Biol Chem 2008; 283: 13952-13963.
37. Zhang H, Ozaki I, Mizuta T, Yoshimura T, Matsuhashi S, Eguchi Y et al. Transforming growth factor-beta 1-induced apoptosis is blocked by beta 1-integrin-mediated mitogen-activated protein kinase activation in human hepatoma cells. Cancer Sci 2004; 95: 878-886.
38. Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. J Exp Clin Cancer Res 2013; 32: 12.
39. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012; 33: 405-412.
40. Lu X, Lu D, Scully M, Kakkar V. The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect Medicin Chem 2008; 2: 57-73.
41. Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 2002; 62: 2535-2539.
42. Ruegg C, Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 2003; 60: 1135-1157.
43. Niland S, Eble JA. Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation. J Oncol 2012; 2012: 125278.
44. Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, Cumashi A et al. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med 2013; 91: 83-94.
45. Natoli C, Dianzani F, Mazzotta F, Balocchini E, Pierotti P, Antonelli G et al. 90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1993; 6: 370-375.
46. Pelliccia P, Natoli C, Petitti MT, Verrotti A, Chiarelli F, Iacobelli S. Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura. J Clin Immunol 1999; 19: 143-147.
47. Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 2003; 48: 2788-2795.
48. Lee YJ, Kang SW, Song JK, Park JJ, Bae YD, Lee EY et al. Serum galectin-3 and galectin-3 binding protein levels in Behcet's disease and their association with disease activity. Clin Exp Rheumatol 2007; 25: S41-S45.
49. Mould AP. Analyzing integrin-dependent adhesion. in: Juan S Bonifacino et al. (eds). Current protocols in cell biology/editorial board, 2011, Chapter 9: Unit 9.4.
50. Mould PA. Solid phase assays for studying ECM protein-protein interactions. Methods Mol Biol 2009; 522: 195-200.
51. Eisenach PA, Roghi C, Fogarasi M, Murphy G, English WR. MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci 2010; 123: 4182-4193.